Insider Trading Alert - CTSH, SNPS, IP, CYBX And UTHR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 18, 2013, 124 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.00 to $864,567,000.00.

Highlighted Stocks Traded by Insiders:

Cognizant Technology Solutions Corporation (CTSH) - FREE Research Report

Klein John E who is Director at Cognizant Technology Solutions Corporation sold 7,275 shares at $93.55 on Dec. 18, 2013. Following this transaction, the Director owned 247,502 shares meaning that the stake was reduced by 2.86% with the 7,275-share transaction.

The shares most recently traded at $96.50, up $2.95, or 3.06% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions Corporation go as follows:

  • 4-Week # shares sold: 31,903
  • 12-Week # shares sold: 35,111
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 153,918

The average volume for Cognizant Technology Solutions Corporation has been 1.8 million shares per day over the past 30 days. Cognizant Technology Solutions Corporation has a market cap of $28.5 billion and is part of the technology sector and computer software & services industry. Shares are up 30.72% year-to-date as of the close of trading on Wednesday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process outsourcing services worldwide. The company operates through four segments: Financial Services; Healthcare; Manufacturing, Retail, and Logistics; and Other. The company has a P/E ratio of 24.2. Currently there are 14 analysts that rate Cognizant Technology Solutions Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings rates Cognizant Technology Solutions Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cognizant Technology Solutions Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Synopsys (SNPS) - FREE Research Report

De Geus Aart who is Chairman of the Board & Co-CEO at Synopsys sold 6,000 shares at $38.90 on Dec. 18, 2013. Following this transaction, the Chairman of the Board & Co-CEO owned 16,000 shares meaning that the stake was reduced by 27.27% with the 6,000-share transaction.

The shares most recently traded at $39.33, up $0.43, or 1.09% since the insider transaction. Historical insider transactions for Synopsys go as follows:

  • 4-Week # shares sold: 16,943
  • 12-Week # shares sold: 16,943
  • 24-Week # shares sold: 39,856

The average volume for Synopsys has been 580,500 shares per day over the past 30 days. Synopsys has a market cap of $6.0 billion and is part of the technology sector and electronics industry. Shares are up 21.91% year-to-date as of the close of trading on Wednesday.

Synopsys, Inc. provides core electronic design automation (EDA) solutions primarily in the United States, Europe, Japan, and the rest of Asia Pacific. The company has a P/E ratio of 15.9. Currently there are 6 analysts that rate Synopsys a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNPS - FREE

TheStreet Quant Ratings rates Synopsys as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Synopsys Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

International Paper (IP) - FREE Research Report

Turner John F who is Director at International Paper sold 8,020 shares at $48.29 on Dec. 18, 2013. Following this transaction, the Director owned 3,997 shares meaning that the stake was reduced by 66.74% with the 8,020-share transaction.

Hoel William P who is Senior Vice President at International Paper sold 4,968 shares at $48.36 on Dec. 18, 2013. Following this transaction, the Senior Vice President owned 0 shares meaning that the stake was reduced by 100% with the 4,968-share transaction.

The shares most recently traded at $48.70, up $0.34, or 0.7% since the insider transaction. Historical insider transactions for International Paper go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 60,000

The average volume for International Paper has been 4.1 million shares per day over the past 30 days. International Paper has a market cap of $21.5 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 24.22% year-to-date as of the close of trading on Wednesday.

International Paper Company operates as a paper and packaging company in North America, Europe, Latin America, Russia, Asia, and North Africa. The stock currently has a dividend yield of 2.9%. The company has a P/E ratio of 18.9. Currently there are 12 analysts that rate International Paper a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IP - FREE

TheStreet Quant Ratings rates International Paper as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, increase in stock price during the past year, compelling growth in net income and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full International Paper Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cyberonics (CYBX) - FREE Research Report

Browne Gregory H who is SR VP Finance & CFO at Cyberonics sold 1,500 shares at $64.60 on Dec. 18, 2013. Following this transaction, the SR VP Finance & CFO owned 69,442 shares meaning that the stake was reduced by 2.11% with the 1,500-share transaction.

The shares most recently traded at $64.07, down $0.53, or 0.83% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 19,411
  • 12-Week # shares sold: 35,516
  • 24-Week # shares sold: 63,361

The average volume for Cyberonics has been 227,000 shares per day over the past 30 days. Cyberonics has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 22.41% year-to-date as of the close of trading on Wednesday.

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 37.8. Currently there are 7 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and increase in stock price during the past year. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

United Therapeutics Corporation (UTHR) - FREE Research Report

Rothblatt Martine A who is Ceo at United Therapeutics Corporation sold 18,149 shares at $86.36 on Dec. 18, 2013. Following this transaction, the Ceo owned 678,272 shares meaning that the stake was reduced by 2.61% with the 18,149-share transaction.

The shares most recently traded at $85.92, down $0.44, or 0.51% since the insider transaction. Historical insider transactions for United Therapeutics Corporation go as follows:

  • 24-Week # shares sold: 1,000

The average volume for United Therapeutics Corporation has been 573,300 shares per day over the past 30 days. United Therapeutics Corporation has a market cap of $4.3 billion and is part of the health care sector and drugs industry. Shares are up 65.84% year-to-date as of the close of trading on Wednesday.

United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. The company has a P/E ratio of 15.6. Currently there are 3 analysts that rate United Therapeutics Corporation a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTHR - FREE

TheStreet Quant Ratings rates United Therapeutics Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full United Therapeutics Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Rises for First Time in 9 Days, Oil Jumps as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Jumps as OPEC Agrees to Boost Output

German Automakers Slump After Trump Tweets New Tariff Threat

German Automakers Slump After Trump Tweets New Tariff Threat

Chipotle Rises After Wedbush Lifts Price Target

Chipotle Rises After Wedbush Lifts Price Target

Crude Rises on OPEC Deal That Doesn't Specify Output Boost

Crude Rises on OPEC Deal That Doesn't Specify Output Boost

Video: Stock Investors Shouldn't Fret About Oil Prices in the $60s

Video: Stock Investors Shouldn't Fret About Oil Prices in the $60s